Combination Drug Therapy for the Management of Alzheimer’s Disease
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/9/3272 |
| _version_ | 1797568749255000064 |
|---|---|
| author | Md. Tanvir Kabir Md. Sahab Uddin Abdullah Al Mamun Philippe Jeandet Lotfi Aleya Rasha A. Mansouri Ghulam Md Ashraf Bijo Mathew May N. Bin-Jumah Mohamed M. Abdel-Daim |
| author_facet | Md. Tanvir Kabir Md. Sahab Uddin Abdullah Al Mamun Philippe Jeandet Lotfi Aleya Rasha A. Mansouri Ghulam Md Ashraf Bijo Mathew May N. Bin-Jumah Mohamed M. Abdel-Daim |
| author_sort | Md. Tanvir Kabir |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD. |
| first_indexed | 2024-03-10T20:01:21Z |
| format | Article |
| id | doaj.art-764d855fee354e23b8a2dd2a77ca9880 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T20:01:21Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-764d855fee354e23b8a2dd2a77ca98802023-11-19T23:32:20ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01219327210.3390/ijms21093272Combination Drug Therapy for the Management of Alzheimer’s DiseaseMd. Tanvir Kabir0Md. Sahab Uddin1Abdullah Al Mamun2Philippe Jeandet3Lotfi Aleya4Rasha A. Mansouri5Ghulam Md Ashraf6Bijo Mathew7May N. Bin-Jumah8Mohamed M. Abdel-Daim9Department of Pharmacy, BRAC University, Dhaka 1212, BangladeshDepartment of Pharmacy, Southeast University, Dhaka 1213, BangladeshDepartment of Pharmacy, Southeast University, Dhaka 1213, BangladeshResearch Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, P.O. Box 1039, 51687 Reims CEDEX 2, FranceChrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, F-25030 Besançon, FranceDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi ArabiaKing Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi ArabiaDivision of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, IndiaDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11474, Saudi ArabiaDepartment of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi ArabiaAlzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.https://www.mdpi.com/1422-0067/21/9/3272combination therapydementiaAlzheimer’s diseasemulti-target-directed ligands |
| spellingShingle | Md. Tanvir Kabir Md. Sahab Uddin Abdullah Al Mamun Philippe Jeandet Lotfi Aleya Rasha A. Mansouri Ghulam Md Ashraf Bijo Mathew May N. Bin-Jumah Mohamed M. Abdel-Daim Combination Drug Therapy for the Management of Alzheimer’s Disease International Journal of Molecular Sciences combination therapy dementia Alzheimer’s disease multi-target-directed ligands |
| title | Combination Drug Therapy for the Management of Alzheimer’s Disease |
| title_full | Combination Drug Therapy for the Management of Alzheimer’s Disease |
| title_fullStr | Combination Drug Therapy for the Management of Alzheimer’s Disease |
| title_full_unstemmed | Combination Drug Therapy for the Management of Alzheimer’s Disease |
| title_short | Combination Drug Therapy for the Management of Alzheimer’s Disease |
| title_sort | combination drug therapy for the management of alzheimer s disease |
| topic | combination therapy dementia Alzheimer’s disease multi-target-directed ligands |
| url | https://www.mdpi.com/1422-0067/21/9/3272 |
| work_keys_str_mv | AT mdtanvirkabir combinationdrugtherapyforthemanagementofalzheimersdisease AT mdsahabuddin combinationdrugtherapyforthemanagementofalzheimersdisease AT abdullahalmamun combinationdrugtherapyforthemanagementofalzheimersdisease AT philippejeandet combinationdrugtherapyforthemanagementofalzheimersdisease AT lotfialeya combinationdrugtherapyforthemanagementofalzheimersdisease AT rashaamansouri combinationdrugtherapyforthemanagementofalzheimersdisease AT ghulammdashraf combinationdrugtherapyforthemanagementofalzheimersdisease AT bijomathew combinationdrugtherapyforthemanagementofalzheimersdisease AT maynbinjumah combinationdrugtherapyforthemanagementofalzheimersdisease AT mohamedmabdeldaim combinationdrugtherapyforthemanagementofalzheimersdisease |